FDA Inspection 680329 — Wuhan Biocause Pharmaceutical Development Co., Ltd.
The FDA completed an inspection of Wuhan Biocause Pharmaceutical Development Co., Ltd. on July 23, 2010 in Wuhan. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- July 23, 2010
- Fiscal Year
- 2010
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Wuhan (China)